| Solventum forecasts annual profit above estimates on strong surgical product sales |
3M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products. |
reuters.com |
2025-02-27 19:09:03 |
Czytaj oryginał (ang.) |
| Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance |
Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3% GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41 Generated $219 million in cash from operations; free cash flow of $92 million Introduces full-year 2025 organic sales growth, adjusted EPS and free cash flow guidance ST. PAUL, Minn. |
prnewswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City |
Learn more about Solventum's long-term strategy to accelerate growth Join in person or via virtual webcast ST. PAUL, Minn. |
prnewswire.com |
2025-02-26 18:15:00 |
Czytaj oryginał (ang.) |
| Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports |
Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. |
reuters.com |
2025-02-26 17:37:56 |
Czytaj oryginał (ang.) |
| Trian Comments on Solventum's Sale of its Purification & Filtration Business |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company's largest active shareholder, commented on Solventum's recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE: TMO) (“Thermo Fisher”). Trian issued the following statement: |
globenewswire.com |
2025-02-26 16:50:00 |
Czytaj oryginał (ang.) |
| Solventum In The Early Stages Of A Multiyear Turnaround Effort |
Solventum In The Early Stages Of A Multiyear Turnaround Effort |
seekingalpha.com |
2025-02-25 12:16:55 |
Czytaj oryginał (ang.) |
| Thermo Fisher buys Solventum's purification and filtration business for $4.1 billion |
Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration business for about $4.1 billion. |
reuters.com |
2025-02-25 10:56:41 |
Czytaj oryginał (ang.) |
| Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B |
Accelerates Solventum's business transformation and sharpens focus on strategic areas for growth to deliver long-term shareholder value Strengthens balance sheet with proceeds to be used primarily for debt paydown ST. PAUL, Minn. |
prnewswire.com |
2025-02-25 10:39:00 |
Czytaj oryginał (ang.) |
| Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business |
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that the company has entered into a definitive agreement with Solventum (NYSE: SOLV) to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as i. |
businesswire.com |
2025-02-25 10:32:00 |
Czytaj oryginał (ang.) |
| Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors |
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. |
globenewswire.com |
2025-02-11 10:00:00 |
Czytaj oryginał (ang.) |
| Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging |
ST. PAUL, Minn. , Feb. 5, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging, has ranked #1 in the 2025 Best in KLAS Awards—Software and Services Report for the fifth time. |
prnewswire.com |
2025-02-05 12:00:00 |
Czytaj oryginał (ang.) |
| Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025 |
Company to host an Investor Day in March 2025 ST. PAUL, Minn. |
prnewswire.com |
2025-01-30 18:05:00 |
Czytaj oryginał (ang.) |
| Billionaire Nelson Peltz Keeps Buying These 2 Stocks Hand Over Fist |
Activist investor Nelson Peltz loves change. Seeking out undervalued and underperforming stocks, the billionaire often takes sizable positions in companies in a bid to unlock shareholder value via improvements in board representation, strategic overhauls, and operational efficiencies. |
247wallst.com |
2025-01-09 18:28:57 |
Czytaj oryginał (ang.) |
| Peltz's Trian Fund says 3M's Solventum spin-off not living up to potential |
Nelson Peltz's Trian Fund Management said in a letter to shareholders on Wednesday that medical device maker Solventum's separation from 3M has not been living up to its potential. |
reuters.com |
2025-01-08 15:38:05 |
Czytaj oryginał (ang.) |
| Trian Issues Open Letter to Solventum Shareholders |
Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company |
globenewswire.com |
2025-01-08 15:01:00 |
Czytaj oryginał (ang.) |
| The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing |
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON , Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Elizabeth Mily as Chief Executive Officer. With more than 30 years of pharma, healthcare investment banking, and strategic leadership experience, Mily will leverage her mission-driven commitment to spearheading the next chapter of the Fund, guiding continued deployment of resources and supporting a comprehensive approach to curing type 1 diabetes. |
prnewswire.com |
2025-01-08 08:30:00 |
Czytaj oryginał (ang.) |
| Solventum to Participate in the Piper Sandler Healthcare Conference |
ST. PAUL, Minn., Nov. 19, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that its executives will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 11:30 a.m. |
prnewswire.com |
2024-11-19 08:50:00 |
Czytaj oryginał (ang.) |
| SOLV Stock Falls Despite Launch of Clarity Precision Grip Attachments |
Solventum's Clarity precision grip attachments enhance treatment outcomes for orthodontic patients, reducing the risk of misplaced and malformed attachments. |
zacks.com |
2024-11-15 10:50:30 |
Czytaj oryginał (ang.) |
| Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment |
Clarity Precision Grip Attachments are fully cured, pre-loaded and precisely resemble the digital treatment plan after bonding ST. PAUL, Minn. |
prnewswire.com |
2024-11-14 11:00:00 |
Czytaj oryginał (ang.) |
| Solventum Corporation (SOLV) Q3 2024 Earnings Call Transcript |
Solventum Corporation (NYSE:SOLV ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Kevin Moran - SVP, IR Bryan Hanson - CEO Wayde McMillan - CFO Conference Call Participants Travis Steed - Bank of America Patrick Wood - Morgan Stanley Vik Chopra - Wells Fargo David Roman - Goldman Sachs Rick Wise - Stifel Ryan Zimmerman - BTIG Jason Bednar - Piper Sandler Chris Senyek - Wolfe Research Operator Good afternoon. My name is Amy, and I will be your conference operator for today. |
seekingalpha.com |
2024-11-08 19:16:14 |
Czytaj oryginał (ang.) |
| SOLV Stock Gains as Q3 Earnings & Sales Beat Estimates, '24 View Up |
Solventum's top line reflects the favorable impact of pricing normalization. Organic growth is primarily driven by rising demand for MedSurg products. |
zacks.com |
2024-11-08 11:31:15 |
Czytaj oryginał (ang.) |
| Solventum raises annual profit forecast on strong surgical product sales |
3M spin-off Solventum raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products. |
reuters.com |
2024-11-07 18:47:52 |
Czytaj oryginał (ang.) |
| Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance |
Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3% GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64 Generated $169 million in cash from operations; free cash flow1 of $76 million Raises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidance ST. PAUL, Minn. |
prnewswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| Solventum Q3 Earnings Likely to Reflect Declining Volume Trend |
SOLV's Q3 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset sales decline. |
zacks.com |
2024-11-06 10:55:29 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now |
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. |
zacks.com |
2024-11-04 11:56:14 |
Czytaj oryginał (ang.) |
| Solventum Taps Bankers to Explore Sale of Filtration Unit |
The business is expected to draw takeover interest from private equity and strategic buyers. |
wsj.com |
2024-10-24 15:33:00 |
Czytaj oryginał (ang.) |
| Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report? |
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2024-10-15 17:15:45 |
Czytaj oryginał (ang.) |
| Solventum to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024 |
ST. PAUL, Minn. , Oct. 15, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. |
prnewswire.com |
2024-10-15 10:50:00 |
Czytaj oryginał (ang.) |
| Solventum Announces Commitment to 100% Renewable Electricity by 2030 |
ST. PAUL, Minn. , Oct. 14, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV), formerly 3M Health Care, today pledges to use 100% renewable electricity across its worldwide operations by 2030. |
prnewswire.com |
2024-10-14 11:00:00 |
Czytaj oryginał (ang.) |
| Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer |
ST. PAUL, Minn. , Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. |
prnewswire.com |
2024-10-10 13:00:00 |
Czytaj oryginał (ang.) |
| Buy 4 October Dividend Aristocrats & Watch 10 |
"Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 10.5%-20.13% topped-by Franklin & Target. |
seekingalpha.com |
2024-10-09 16:17:05 |
Czytaj oryginał (ang.) |
| SOLV or MEDP: Which Is the Better Value Stock Right Now? |
Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2024-10-03 16:46:22 |
Czytaj oryginał (ang.) |
| Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped |
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management. |
247wallst.com |
2024-09-29 15:32:12 |
Czytaj oryginał (ang.) |
| 26 Millionaires and Billionaires Can't Be Wrong. The One Stock All of Them Are Buying |
Watching what the smart money is buying can be a useful investment strategy. |
247wallst.com |
2024-09-28 17:05:09 |
Czytaj oryginał (ang.) |
| Billionaire Nelson Peltz Unveiled 3 New Stocks in His Very Focused Portfolio |
Nelson Peltz isn't one to shy away from a fight. |
247wallst.com |
2024-09-28 14:28:59 |
Czytaj oryginał (ang.) |
| SOLV vs. DOCS: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-09-16 16:46:19 |
Czytaj oryginał (ang.) |